FDA approves Moderna’s first mRNA flu shot for adults 50+, enabling faster strain matching
TL;DR
The FDA approved Moderna’s mFLUSIVA (mRNA-1010), the first mRNA-based seasonal flu vaccine, for adults 50 and older, based on phase 3 data showing superior protection against flu-like illness versus standard vaccines; accelerated approval for 65+, with post‑approval confirmatory data required. The vaccine can be produced more quickly to better match evolving influenza strains, potentially adding an important option without replacing existing vaccines; common vaccine side effects apply, and availability is anticipated for the 2026–2027 season.
- Moderna's mRNA flu vaccine approved by FDA. When is it available? Medical News Today
- There’s a new type of flu vaccine for older adults this year. Can you get it? Times Union
- Moderna's Comeback Is Finally Taking Shape -- and There May Be More Upside Ahead Yahoo Finance
- RNA researcher on the basics of how mRNA vaccines are made and work UC Santa Cruz - News
- Navigating the New mRNA Flu Shot: A Discussion With Dr William Schaffner Medical Professionals Reference
Want the full story? Read the original reporting
Read on Medical News Today